Brief: Relief Therapeutics Subsidiary Signs Agreement To Commercialize Novel Dosage Form For PKU Treatment

MindMaze Therapeutics Holding SA

15/03/2022 06:16

March 15 (Reuters) - RELIEF THERAPEUTICS HOLDING SA
 RLFB.S :
    * RELIEF THERAPEUTICS' WHOLLY OWNED SUBSIDIARY, APR APPLIED
PHARMA
RESEARCH SIGNS AN AGREEMENT TO ACQUIRE RIGHTS TO COMMERCIALIZE A
NOVEL DOSAGE FORM FOR THE TREATMENT OF PKU
    * HAS SIGNED A BINDING TERM SHEET WITH META HEALTHCARE LTD.
TO
ACQUIRE WORLDWIDE COMMERCIALIZATION RIGHTS, EXCEPT IN UK AND
IRELAND, FOR A NOVEL DOSAGE FORM OF A PRESCRIPTION DRUG ALREADY
APPROVED BY U.S. FDA AND INTENDED FOR TREATMENT OF PATIENTS WITH
PHENYLKETONURIA
    * FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED

Source text for Eikon:  ID:nEQ8djPRra 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))